-
-
-
-
-
-
-
Merck and Moderna report Phase 3 melanoma trial results
-
-
-
-
-
-
-
Moderna (MRNA) on Watch Following Chatter of Positive Data
-
-
-
-
-
-
-
Tempus expands collaboration with Moderna and Merck on cancer therapy
-
-
-
-
-
-
-
Moderna (MRNA) call put ratio 1.4 calls to 1 put into share price lower before the bell
-
-
-
-
-
-
-
Moderna (MRNA) spreader of 1K contracts of September 25 weekly 157.50 and 165 calls as share price up 10.5%
-
-
-
-
-
-
-
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
-
-
-
-
-
-
-
Moderna (MRNA) call put ratio 1.1 calls to 1 put amid sharp rally
-
482,974 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


